期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 13, 期 5, 页码 699-715出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.2012.667803
关键词
adverse effect profiles; drug-drug interactions; efficacy profiles; eslicarbazepine acetate; lacosamide; novel mechanisms of action; pharmacokinetics; retigabine; therapeutic drug monitoring; third-generation antiepileptic drugs
资金
- Eisai
- GlaxoSmithKline
- Johnson and Johnson
- Novartis
- Pfizer
- Sanofi-Aventis
- UCB Pharma
- Department of Health's NIHR
Introduction: The search for new, more effective antiepileptic drugs (AEDs) continues. The three most recently approved drugs, the so-called third-generation AEDs, include lacosamide, retigabine and eslicarbazepine acetate and are licensed as adjunctive treatment of partial epilepsy in adults. Areas covered: For the above three AEDs, their mechanisms of action, pharmacokinetic characteristics, drug-drug interactions, pharmacotherapeutics, dose and administration and therapeutic drug monitoring are reviewed in this paper. Expert opinion: Lacosamide and retigabine act through novel mechanisms, while eslicarbazepine acetate, a pro-drug for eslicarbazepine, acts in a similar manner to several other AEDs. All three AEDs are associated with linear pharmacokinetic and rapid absorption and undergo metabolism. Their drug-drug interaction profile is low (lacosamide and retigabine) to modest (eslicarbazepine) in propensity. At the highest approved doses for the three AEDs, responder rates were similar. The most commonly observed adverse effects compared with placebo were dizziness, headache, diplopia and nausea for lacosamide; dizziness, somnolence and fatigue for retigabine and dizziness and somnolence for eslicarbazepine acetate. The precise role that these new AEDs will have in the treatment of epilepsy and whether they will make a significant impact on the prognosis of intractable epilepsy is not yet known and will have to await further clinical experience.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据